Iovance Biotherapeutics Announces Upcoming Conference Appearances
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a pioneering biotechnology firm dedicated to advancing treatments through innovative polyclonal tumor infiltrating lymphocyte (TIL) therapies, has revealed that its senior executive team will be showcasing their expertise at several prestigious conferences in the near future.
Presentation Schedule
The first major event on their calendar is the 2025 Wells Fargo Healthcare Conference, where the leadership will engage in a fireside chat on September 5, 2025, at 8:00 a.m. ET. Following this, the company will participate in the H.C. Wainwright 27th Annual Global Investment Conference, featuring a presentation scheduled for September 9, 2025, at 11:00 a.m. ET.
Live Webcasts Availability
For those who are unable to attend these presentations in person, live and archived webcasts will be accessible online, providing insights into the company’s advancements and strategies. This access is crucial for investors and interested parties wishing to stay informed about Iovance's progress in the biotechnology field.
About Iovance Biotherapeutics
Iovance Biotherapeutics is on a mission to lead the global charge in innovating, developing, and distributing TIL therapies for cancer patients. With a commitment to harnessing the robust capabilities of the human immune system, the company seeks to create groundbreaking cancer treatments tailored to the diverse characteristics of tumors in each individual.
Innovative Treatment Technologies
The Iovance TIL platform remains at the forefront of clinical advancements, presenting promising results across a variety of solid tumors. Among its notable achievements is Amtagvi, recognized as the first FDA-approved T cell therapy specifically for solid tumors. Iovance strives to continue its path of innovation not just in TIL therapies but also in exploring gene-edited cell therapies that hold the potential to significantly enhance and extend patients' lives.
Contact Information for Inquiries
For further information or queries, interested parties can reach out via the following channels:
Investors:
IR@iovance.com
Phone: 650-260-7120 ext. 150
Media:
PR@iovance.com
Phone: 650-260-7120 ext. 150
Frequently Asked Questions
What is Iovance Biotherapeutics known for?
Iovance Biotherapeutics specializes in innovative cancer treatments utilizing tumor infiltrating lymphocyte (TIL) therapies.
When are the upcoming conferences?
Iovance is scheduled to present at the Wells Fargo Healthcare Conference on September 5 and the H.C. Wainwright Annual Conference on September 9, 2025.
How can I access the webcasts?
Webcasts of the presentations will be available live and archived online for those interested in Iovance's developments.
What are TIL therapies?
TIL therapies involve extracting and expanding the immune cells that infiltrate tumors, then reinfusing them to help combat cancer.
How can I contact Iovance for more information?
For inquiries, individuals can reach the Investor Relations or Media departments via the email addresses provided above.
